The FDA’s recent approval of Pfizer’s migraine nasal spray was also good news for Royalty Pharma, triggering a whopping $475 million milestone payment
March 10 (Reuters) - The U.S. Food and Drug Administration on Friday approved Pfizer Inc's (PFE.N) nasal spray for migraine, giving patients access to a potentially fast-acting pain-relief option for headaches.
EXTON, Pa., Feb. 28, 2023 /PRNewswire/ -- On February 16, The Lancet Neurology published the Phase 3 results of Pfizer's zavegepant for the acute treatment of migraine. The CGRP receptor antagonist nasal spray has met its co-primary endpoints that a single 10mg dose proved to be more effective than placebo for both pain freedom and freedom from the most bothersome symptom (MBS) at two-hours post-dose. Zavegepant provided relief from migraine pain in 15 minutes, lasting up to 48 hours, according to the release.
Pfizer Announces The Lancet Neurology Has Published Phase 3 Data for Zavegepant for the Acute Treatment of Migraine in Adults
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for ...
Five years ago to the day, Biohaven tied a bow around its IPO and launched onto Wall Street equipped with almost $200 million and the ambition of its founders to bust open the migraine market. Fast-forward to 2022 and by all counts, consider it mission accomplished.
Biohaven Pharmaceutical Holding Company Ltd. BHVN announced positive top-line data from the second pivotal study evaluating the safety and efficacy of its intranasal CGRP receptor antagonist, zavegepant, for the acute treatment of migraine in adults. The study met its co-primary endpoints of pain freedom and freedom from most bothersome symptom at two hours.
Pfizer has signed a collaboration and licence agreement to obtain rights to market Biohaven Pharmaceutical’s migraine drugs, rimegepant and zavegepant, outside the US.
Biohaven Pharmaceutical, a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, announced that it enrolled the first patient in a phase 2/3, double-blind, randomized, placebo-controlled, dose-ranging trial of intranasally administered BHV-3500 for the acute treatment of migraine. BHV-3500 is a novel, structurally distinct, third-generation calcitonin gene-related peptide (CGRP) receptor antagonist being developed by Biohaven